Whalesbook
Fund Utilization and Demerger Advance
Religare Enterprises has confirmed that ₹380.82 crore from its ₹1,500 crore preferential issue was utilized by March 31, 2026. Funds have been deployed into key subsidiaries and for debt repayment. The company's board has also approved a significant demerger of its financial services business into Religare Finvest Ltd., with planned completion by the first quarter of FY28.
A report from CARE Ratings verifies that Religare Enterprises is using the preferential issue proceeds as intended. Specific deployments include ₹256.10 crore into Care Health Insurance and ₹25.00 crore into Religare Broking. An additional ₹75.00 crore was used for repaying borrowings, strengthening the company's balance sheet. However, Religare Enterprises reported standalone losses for the last three quarters of the fiscal year ended March 31, 2026.
Strategic Significance
This capital utilization update addresses investor questions about fund deployment for growth engines and debt reduction. The board's approval to demerge the financial services business into Religare Finvest signals a major corporate restructuring aimed at unlocking shareholder value.
Turnaround Strategy
Under the Burman family's leadership, Religare Enterprises has pursued a significant turnaround strategy, focusing on restructuring operations and strengthening its financial position. The demerger is a key step in creating distinct, focused business verticals.
Demerger Impact
Shareholders of Religare Enterprises will receive shares in the demerged Religare Finvest Limited on a 1:1 basis. This move will establish the financial services business as a separate, potentially listed, entity. The company targets the completion and listing of Religare Finvest by Q1 FY28.
Key Risks and Approvals
The demerger process is dependent on obtaining various regulatory and stakeholder approvals, including from SEBI, RBI, and NCLT. Persistent standalone losses in FY26 raise concerns about the core entity's underlying profitability. The current market price of Religare Enterprises (₹224) is below the preferential issue price of ₹235 per warrant, though it remains above the call amount of ₹176.25.
Industry Landscape
- IIFL Group: Similar to Religare's strategy, IIFL Group also manages diversified financial services. Religare's demerger mirrors industry moves to unlock value from specialized units.
- Angel One: Competes with Religare Broking. Angel One's strong digital growth highlights the competitive intensity in the broking sector.
- ICICI Lombard: Care Health Insurance operates in the health insurance market, facing comparable regulatory pressures and growth opportunities as established players like ICICI Lombard.
Key Financial Metrics
- Preferential Issue Size: ₹1,500.00 crore (FY25–FY26)
- Utilized Preferential Issue Proceeds: ₹380.82 crore (As of March 31, 2026)
- Investment in Care Health Insurance: ₹256.10 crore (As of March 31, 2026)
- Investment in Religare Broking: ₹25.00 crore (As of March 31, 2026)
- Borrowings Repaid: ₹75.00 crore (As of March 31, 2026)
Investor Watchlist
- Monitor progress and timelines for crucial demerger regulatory approvals.
- Track the financial performance of the standalone entity and its subsidiaries.
- Observe the allocation strategy for remaining preferential issue funds.
- Watch for milestones toward the targeted listing of Religare Finvest by Q1 FY28.